Asset
ETIRINOTECAN PEGOL
Nektar Therapeutics Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01976143 | phase1 | completed | 2014-02-01 | 2016-06-01 | Nektar Therapeutics | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety |
| NCT02915744 | phase3 | completed | 2016-11-01 | 2020-07-01 | Nektar Therapeutics | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine |
| NCT01457118 | phase2 | completed | 2011-10-01 | 2017-08-01 | Nektar Therapeutics | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies |
| NCT00856375 | phase2 | completed | 2008-12-01 | 2014-07-01 | Nektar Therapeutics | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer |
| NCT00598975 | phase2 | completed | 2008-02-01 | 2009-05-01 | Nektar Therapeutics | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) |
FDA applications (0)
This company has no applications containing this asset.